Payment overview · 2025
General Payments
$377.83
21 reported records · 11 companies
Healthcare provider profile · identity verified
Trina C Chapman-Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, IN · NPI 1285634568
Verified facts
What the public records show
CMS Open Payments records show Trina C Chapman-Smith, MD received $377.83 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.75 | 28.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.87 | 14.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.83 | 14.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.38 | 9.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.10 | 8.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.63 | 6.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.48 | 4.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.63 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.30 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.24 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.62 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.83 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.23 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.38 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $30.62 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 351 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 45 |
| Lisinopril | Lisinopril | 171 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 46 |
| Gabapentin | Gabapentin | 151 | 48 |
| Losartan Potassium | Losartan Potassium | 150 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 43 |
| Omeprazole | Omeprazole | 140 | 42 |
| Metformin Hcl | Metformin Hcl | 133 | 35 |
| Carvedilol | Carvedilol | 119 | 36 |
| Eliquis | Apixaban | 106 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 33 |
| Meloxicam | Meloxicam | 96 | 30 |
| Tramadol Hcl | Tramadol Hcl | 96 | 26 |
| Prednisone | Prednisone | 90 | 66 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 17 |
| Furosemide | Furosemide | 75 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 22 |
| Trazodone Hcl | Trazodone Hcl | 69 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 16 |
| Alprazolam | Alprazolam | 59 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 22 |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Famotidine | Famotidine | 57 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Jardiance | Empagliflozin | 50 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 13 |
| Potassium Chloride | Potassium Chloride | 45 | 16 |
| Allopurinol | Allopurinol | 43 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Levofloxacin | Levofloxacin | 41 | 24 |
| Metformin Hcl Er | Metformin Hcl | 41 | 11 |
| Celecoxib | Celecoxib | 40 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 13 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 17 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Fluconazole | Fluconazole | 31 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 12 |
| Topiramate | Topiramate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 18 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 16 |
| Simvastatin | Simvastatin | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.83 · 21 records | Novo Nordisk Inc | Auvelity, BREZTRI, COMIRNATY, JOURNAVX, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VYEPTI, VYNDAQEL, Wegovy, ZAVZPRET, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error